tiprankstipranks
Recursion Pharmaceuticals (RXRX)
NASDAQ:RXRX
US Market

Recursion Pharmaceuticals (RXRX) Income Statement

Compare
2,843 Followers

Recursion Pharmaceuticals Income Statement

Last quarter (Q3 2024), Recursion Pharmaceuticals's total revenue was $26.08M, an increase of 158.19% from the same quarter last year. In Q3, Recursion Pharmaceuticals's net income was $-95.67M. See Recursion Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 44.58M$ 39.68M$ 10.00M$ 3.41M$ 1.71M
Gross Profit
$ 1.99M$ -8.59M$ 896.00K$ -59.91M$ -44.10M
Operating Expenses
$ 351.35M$ 237.13M$ 192.78M$ 88.03M$ 64.15M
Depreciation and Amortization
$ 24.40M$ 19.49M$ 9.10M$ 4.44M$ 3.54M
EBITDA
$ -299.57M$ -227.66M$ -174.42M$ -81.70M$ -58.34M
Operating Income
$ -350.06M$ -245.73M$ -182.78M$ -84.61M$ -62.44M
Other Income/Expenses
$ 17.93M$ 6.25M$ -3.70M$ -2.39M$ 562.00K
Pretax Income
$ -332.13M$ -239.48M$ -186.48M$ -87.01M$ -61.88M
Net Income
$ -328.07M$ -239.42M$ -178.07M$ -87.88M$ -62.52M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -1.58$ -1.36$ -1.05$ -0.52$ -0.37
Diluted EPS
$ -1.58$ -1.36$ -1.05$ -0.52$ -0.37
Weighted Average Shares Outstanding
207.85M 175.54M 170.27M 165.79M 165.79M
Weighted Average Shares Outstanding (Diluted)
207.85M 175.54M 170.27M 165.79M 165.79M
Currency in USD

Recursion Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis